MacroGenics, Inc. (MGNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGNX POWR Grades
- MGNX scores best on the Value dimension, with a Value rank ahead of 61.02% of US stocks.
- The strongest trend for MGNX is in Stability, which has been heading up over the past 179 days.
- MGNX ranks lowest in Momentum; there it ranks in the 4th percentile.
MGNX Stock Summary
- Of note is the ratio of Macrogenics Inc's sales and general administrative expense to its total operating expenses; merely 9.64% of US stocks have a lower such ratio.
- As for revenue growth, note that MGNX's revenue has grown -26.16% over the past 12 months; that beats the revenue growth of only 6.14% of US companies in our set.
- In terms of volatility of its share price, MGNX is more volatile than 87.72% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Macrogenics Inc, a group of peers worth examining would be IMGN, CLLS, ABUS, LPTX, and ATHX.
- Visit MGNX's SEC page to see the company's official filings. To visit the company's web site, go to www.macrogenics.com.
MGNX Valuation Summary
- MGNX's EV/EBIT ratio is -9.9; this is 133.79% lower than that of the median Healthcare stock.
- MGNX's EV/EBIT ratio has moved up 169 over the prior 96 months.
- Over the past 96 months, MGNX's EV/EBIT ratio has gone up 169.
Below are key valuation metrics over time for MGNX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MGNX | 2021-08-31 | 12.2 | 4.5 | -11.2 | -9.9 |
| MGNX | 2021-08-30 | 12.0 | 4.5 | -11.0 | -9.8 |
| MGNX | 2021-08-27 | 12.2 | 4.5 | -11.2 | -9.9 |
| MGNX | 2021-08-26 | 11.7 | 4.4 | -10.7 | -9.5 |
| MGNX | 2021-08-25 | 11.6 | 4.3 | -10.7 | -9.4 |
| MGNX | 2021-08-24 | 12.0 | 4.5 | -11.0 | -9.8 |
MGNX Growth Metrics
- Its year over year net cashflow from operations growth rate is now at 34.78%.
- The 5 year cash and equivalents growth rate now stands at -38.76%.
- Its 5 year price growth rate is now at -60.95%.
The table below shows MGNX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 77.447 | -143.83 | -202.115 |
| 2021-09-30 | 115.991 | -95.054 | -146.18 |
| 2021-06-30 | 118.582 | -105.936 | -129.337 |
| 2021-03-31 | 108.082 | -96.792 | -136.287 |
| 2020-12-31 | 104.883 | -111.898 | -129.739 |
| 2020-09-30 | 77.384 | -144.409 | -158.048 |
MGNX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MGNX has a Quality Grade of C, ranking ahead of 36.14% of graded US stocks.
- MGNX's asset turnover comes in at 0.284 -- ranking 156th of 681 Pharmaceutical Products stocks.
- SRNE, CNCE, and VBLT are the stocks whose asset turnover ratios are most correlated with MGNX.
The table below shows MGNX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.284 | 0.985 | -0.809 |
| 2021-06-30 | 0.294 | 1.000 | -0.724 |
| 2021-03-31 | 0.285 | 1.000 | -0.860 |
| 2020-12-31 | 0.312 | 1.000 | -0.859 |
| 2020-09-30 | 0.242 | 1.000 | -1.055 |
| 2020-06-30 | 0.248 | 1.000 | -1.081 |
MGNX Price Target
For more insight on analysts targets of MGNX, see our MGNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $36.25 | Average Broker Recommendation | 1.45 (Moderate Buy) |
MGNX Stock Price Chart Interactive Chart >
MGNX Price/Volume Stats
| Current price | $3.98 | 52-week high | $32.81 |
| Prev. close | $3.90 | 52-week low | $3.76 |
| Day low | $3.79 | Volume | 815,500 |
| Day high | $4.15 | Avg. volume | 669,944 |
| 50-day MA | $7.47 | Dividend yield | N/A |
| 200-day MA | $15.12 | Market Cap | 244.11M |
MacroGenics, Inc. (MGNX) Company Bio
Macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company was founded in 2000 and is based in Rockville, Maryland.
Latest MGNX News From Around the Web
Below are the latest news stories about Macrogenics Inc that investors may wish to consider to help them evaluate MGNX as an investment opportunity.
MacroGenics to Participate in Upcoming Investor ConferencesROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2022: Cowen 42nd Annual Health Care Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate on the Gastrointestinal/Ge |
What 4 Analyst Ratings Have To Say About MacrogenicsAnalysts have provided the following ratings for Macrogenics (NASDAQ: MGNX ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 3 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Macrogenics. The company has an average price target of $28.75 with a high of $40.00 and a low of $21.00. Below is a summary of how these 4 analysts rated Macrogenics over the past 3 months. The greater the number of bullish ratings, … Full story available on Benzinga.com |
MacroGenics upgraded to buy at Citi on valuationCiti has upgraded MacroGenics (MGNX) to buy from neutral saying the company''s pipeline has "entered undervalued territory." |
MacroGenics Announces Executive PromotionROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced today that it has promoted Eric Risser to Chief Operating Officer, as of February 22. Mr. Risser joined MacroGenics in 2009 and has played an instrumental leadership role in sourcing, structuring and negotiating the company's collaboration partnerships and has been res |
MacroGenics: Facing Considerable Headwinds From Unsatisfactory TrialsNo summary available. |
MGNX Price Returns
| 1-mo | -49.04% |
| 3-mo | N/A |
| 6-mo | -78.96% |
| 1-year | -86.70% |
| 3-year | -78.64% |
| 5-year | -79.57% |
| YTD | -75.20% |
| 2021 | -29.79% |
| 2020 | 110.11% |
| 2019 | -14.33% |
| 2018 | -33.16% |
| 2017 | -7.05% |
Continue Researching MGNX
Want to do more research on Macrogenics Inc's stock and its price? Try the links below:Macrogenics Inc (MGNX) Stock Price | Nasdaq
Macrogenics Inc (MGNX) Stock Quote, History and News - Yahoo Finance
Macrogenics Inc (MGNX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...